Should not be used in patients w/ type 1 diabetes. Patients at risk of ketoacidosis while on treatment include patients on a very low carbohydrate diet, w/ an acute illness, pancreatic disorders suggesting insulin deficiency (eg, type 1 diabetes, history of pancreatitis or pancreatic surgery), insulin dose reduction (including insulin pump failure), alcohol abuse, severe dehydration & history of ketoacidosis. Discontinue treatment if Fournier's gangrene, pancreatitis or bullous pemphigoid is suspected. Concomitant use w/ sulphonylurea or insulin. Assess renal function prior to the initiation of treatment & periodically during treatment. Patients for whom an empagliflozin-induced decrease in BP could pose a risk eg, patients w/ known CV disease, on anti-hypertensive therapy w/ history of hypotension. In conditions that may lead to fluid loss (eg, GI illness), monitor vol status (eg, physical exam, BP measurements, lab tests including haematocrit) & electrolytes. Complicated UTI (including pyelonephritis & urosepsis). Not recommended in patients w/ renal impairment (eGFR is persistently <30 mL/min/1.73 m
2). Pregnancy & lactation. Not recommended for use in childn <18 yr. Increased risk of vol depletion in elderly ≥75 yr.
Sign Out
